Request for membership to create or review content for BOPA Digital SACT passport

Dear Member,

It has been 12 months since the launch of the “BOPA SACT Verification Passport”.
In order to optimise user experience of the Passport, we need to have new and relevant content.
The Passport working group would like to ask the paying BOPA members for assistance in the creation and review of this content.

How do you contribute?

We request that you register interest to be a creator and/or reviewer of Mock Prescriptions via the following link:

https://www.bopa.org.uk/mock-rx-creator-reviewer-registration/

You can also register within the BOPA SACT Verification Hub in the Contribution to Content tile.

Our mock prescription team will be in touch and will allocate you the required mock prescription content based on your indicated role, level of verification and speciality, and will advise from there.
This is to prevent duplication of entries.

We greatly appreciate any and all contributions to the ongoing use and success of the Passport and encourage all members to get involved in the creation of content.

Please see the relevant supportive SOPs for this process which are saved within the SOP tile of the BOPA SACT Verification Hub.

If you have any queries about this process, please get it touch via email ([email protected])

Kind Regards,

BOPA Passport Pillar

 

Please appreciate these are for UK-wide use and are not unique to any one nation, Trust or cancer centre. Content may not reflect your local practice.

Latest News

By BOPA Executive Committee on 25th April 2025

NICE TA: Ribociclib with an aromatase inhibitor can be used as an option for the adjuvant treatment of hormone receptor-positive, HER2-negative, early breast cancer at high risk of recurrence in adults.

BOPA have been involved with the following NICE TA: Ribociclib with an aromatase inhibitor can be used as an option for the adjuvant treatment of hormone receptor-positive, HER2-negative, early breast cancer…

Read article
By BOPA IO SAG on 23rd April 2025

Toolkit for Immunotherapy IV to SC switch

Dear all, In the coming months, an increasing number of products traditionally administered intravenously are expected to become available for subcutaneous administration. This shift offers enhanced flexibility for patients; however,…

Read article
By BOPA E&T subcommittee on 17th April 2025

The BOPA Cancer Consultant Pharmacist Credentialing Support Series is back

BOPA are holding a nine month supportive webinar series for pharmacists who are credentialing as consultant pharmacists with the RPS. Join in this relaxed forum to discuss about your portfolio…

Read article
By BOPA research subcommittee on 17th April 2025

Celebration of BOPA member’s recent publications

We are delighted to share that so many of our members have had manuscripts published recently. Here are some that we are aware of but if there are others then…

Read article